UBS Ups BrightSpring Target to $42, Reiterated Buy After Beat-and-Raise Q3

BrightSpring Health Services, Inc. (NASDAQ:BTSG) is one of the best digital health stocks to buy now.

On October 29, one day after the company's release of Q3 results, UBS analyst A.J. Rice. reiterated Buy and lifted their 12-month price target to $42 (from $35), citing a classic “beat-and-raise” quarter and management’s confidence, especially around specialty/infusion momentum carrying into 2026.

On October 28, BrightSpring Health Services, Inc. (NASDAQ:BTSG) reported revenue of $3.334 billion (+28.2% YoY), adjusted EBITDA of $160 million (+37.2% YoY), and net income of $37.5 million versus a prior-year loss.

Photographee.eu/Shutterstock.com

The mix did the heavy lifting: Pharmacy Solutions grew ~31% to $2.97 billion on specialty and infusion strength, while Provider Services rose ~9% to $367 million. Management raised FY25 revenue guidance to $12.4–$12.7 billion and kept adjusted EBITDA at $605–$615 million, pointing to continued specialty volume, limited-distribution drug adds, and execution on the pharmacy platform.

BrightSpring Health Services, Inc. (NASDAQ:BTSG) is a post-acute care company offering home and community-based clinical services, as well as pharmacy solutions, across the United States. It serves medically complex and aging populations through a mix of in-home care, behavioral health support, and medication management.

While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None.